FDA Approves GSK’s Arexvy, the First RSV Vaccine for Older Adults
GSK plc stated that the US Food and Drug Administration (FDA) has approved Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by a respiratory syncytial virus (RSV) in people aged 60 and up. This is the first RSV vaccine for older individuals to be licensed anywhere globally.
"Today marks a turning point in our effort to reduce the significant burden of RSV," said Tony Wood, Chief Scientific Officer of GSK. Arexvy is the first RSV vaccine authorized for older adults, adding to GSK's industry-leading vaccination portfolio, w...
